NCT00509366 - Study Using a Genomic Predictor of Platinum Resistance to Guide Therapy in Stage IIIB/IV Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

May 31, 2007

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Non Small Cell Lung Cancer

Interventions

DRUG

Cisplatin & Gemcitabine

"Squamous Cell NSCLC:~Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"

DRUG

Cisplatin & Pemetrexed

"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"

DRUG

Docetaxel & Gemcitabine

"Squamous Cell NSCLC:~Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"

DRUG

Pemetrexed & Gemcitabine

"Non-Squamous Cell NSCLC:~Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"

Trial Locations (8)

23970

Community Memorial Health Center, South Hill

27536

Maria Parham Hospital, Henderson

27609

Duke Raleigh Hospital, Raleigh

27710

Duke University Medical Center, Durham

28352

Scotland HealthCare System (Scotland Memorial Hospital), Laurinburg

28358

Southeastern Regional Medical Center, Gibson Cancer Center, Lumberton

29572

Coastal Cancer Center, Myrtle Beach

29902

Beaufort Memorial Hospital, Beaufort